Journal of Hepatology

Peter Ferenci
No abstract text is available yet for this article.
November 5, 2019: Journal of Hepatology
Stephen A Harrison, Naim Alkhouri, Beth A Davison, Arun Sanyal, Christopher Edwards, Jerry R Colca, Bo Hyun Lee, Rohit Loomba, Kenneth Cusi, Orville Kolterman, Gad Cotter, Howard C Dittrich
BACKGROUND & AIMS: MSDC-0602K is a novel insulin sensitizer designed to preferentially target the mitochondrial pyruvate carrier while minimizing direct binding to the transcriptional factor PPARγ. Herein, we aimed to assess the efficacy and safety of MSDC-0602K in patients with non-alcoholic steatohepatitis. METHODS: Patients with biopsy-confirmed NASH and fibrosis (F1-F3) were randomized to daily oral placebo, or 1 of 3 MSDC-0602K doses in a 52-week double-blind study...
November 4, 2019: Journal of Hepatology
Robert S Brown, Maria Buti, Lino Rodrigues, Vladimir Chulanov, Wan-Long Chuang, Humberto Aguilar, Gábor Horváth, Elimelech Zuckerman, Barbara Rosado Carrion, Federico Rodriguez-Perez, Petr Urbánek, Armand Abergel, Eric Cohen, Sandra S Lovell, Gretja Schnell, Chih-Wei Lin, Jiuhong Zha, Stanley Wang, Roger Trinh, Federico J Mensa, Margaret Burroughs, Franco Felizarta
BACKGROUND & AIMS: 8-week glecaprevir/pibrentasvir demonstrates high rates of sustained virological response at post-treatment week 12 (SVR12) across hepatitis C virus (HCV) genotypes (GT) 1-6 in treatment-naïve patients without cirrhosis. We evaluated glecaprevir/pibrentasvir once daily for 8 weeks in treatment-naïve patients with compensated cirrhosis. METHODS: EXPEDITION-8 was a single-arm, multicenter, phase 3b trial. The primary and key secondary efficacy analyses were to compare the lower bound of the 95% confidence interval (CI) of the SVR12 rate in (1) patients with GT1,2,4-6 in the per-protocol (PP) population, (2) patients with GT1,2,4-6 in the intention-to-treat (ITT) population, (3) patients with GT1-6 in the PP population, and (4) patients with GT1-6 in the ITT population, to pre-defined efficacy thresholds based on historical SVR12 rates for 12 weeks of glecaprevir/pibrentasvir in the same populations...
November 1, 2019: Journal of Hepatology
Toru Ikegami, Tomoharu Yoshizumi, Takahiro Tomiyama, Shoichi Inokuchi, Masaki Mori
No abstract text is available yet for this article.
October 31, 2019: Journal of Hepatology
William Bernal, Stephen H Caldwell, Ton Lisman
No abstract text is available yet for this article.
October 29, 2019: Journal of Hepatology
Vinay Sundaram, Shannon Kogachi, Robert J Wong, Constantine J Karvellas, Brett E Fortune, Nadim Mahmud, Josh Levitsky, Robert S Rahimi, Rajiv Jalan
BACKGROUND AND AIMS: We evaluated whether the clinical course of acute on chronic liver failure (ACLF) between time of listing and liver transplantation (LT) affects one-year post-transplant survival. METHODS: We identified patients from the UNOS database who were transplanted within 28 days of listing, and categorized them by ACLF grade at waitlist registration and LT, per the EASL-CLIF definition. RESULTS: 3,636 patients listed with ACLF-3 underwent LT within 28-days...
October 25, 2019: Journal of Hepatology
Maryam Alavi, Matthew G Law, Gregory J Dore
No abstract text is available yet for this article.
October 24, 2019: Journal of Hepatology
Thomas Yau, Chiun Hsu, Tae-You Kim, Su-Pin Choo, Yoon-Koo Kang, Ming-Mo Hou, Kazushi Numata, Winnie Yeo, Akhil Chopra, Masafumi Ikeda, Ryoko Kuromatsu, Michihisa Moriguchi, Yee Chao, Huanyu Zhao, Jeffrey Anderson, Christine Dela Cruz, Masatoshi Kudo
No abstract text is available yet for this article.
October 24, 2019: Journal of Hepatology
Gregory J Dore, Jordan J Feld, Alex Thompson, Marianne Martinello, Andrew J Muir, Kosh Agarwal, Beat Müllhaupt, Heiner Wedemeyer, Karine Lacombe, Gail V Matthews, Michael Schultz, Marina Klein, Christophe Hezode, Gerard Estivill Mercade, Danny Kho, Kathy Petoumenos, Philippa Marks, Fernando Tatsch, Ana Gabriela Pires Dos Santos, Ed Gane
BACKGROUND AND AIMS: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) has high efficacy and limited toxicity. We hypothesised that efficacy of glecaprevir-pibrentasvir for chronic HCV with a simplified treatment monitoring schedule would be non-inferior to a standard treatment monitoring schedule. METHODS: In this open-label multicentre phase 3b trial, treatment-naïve adults with chronic HCV without cirrhosis were randomly assigned (2:1) to receive glecaprevir-pibrentasvir 300mg-120mg daily for eight weeks administered with a simplified or standard monitoring strategy...
October 23, 2019: Journal of Hepatology
Paola Dongiovanni, Annalisa Crudele, Nadia Panera, Ilaria Romito, Marica Meroni, Cristiano De Stefanis, Alessia Palma, Donatella Comparcola, Anna Ludovica Fracanzani, Luca Miele, Luca Valenti, Valerio Nobili, Anna Alisi
BACKGROUND AND AIM: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in adults and children. Along with obesity, diabetes and insulin resistance, genetic factors strongly impact on NAFLD development and progression. Dysregulated bile acid metabolism and the fibroblast growth factor 19 (FGF19) pathway play a pivotal role in NAFLD pathogenesis. However, it remains to be defined the mechanism through which the FGF19 receptor system is associated with liver damage in NAFLD...
October 23, 2019: Journal of Hepatology
James Wilton, Hasina Samji, Amanda Yu, Mel Krajden, Naveed Zafar Janjua
No abstract text is available yet for this article.
October 22, 2019: Journal of Hepatology
Lauren Lapointe-Shaw, Peter C Austin, Hannah Chung, Beate Sander, Jeffrey C Kwong, Jordan J Feld
No abstract text is available yet for this article.
October 21, 2019: Journal of Hepatology
Jean-Michel Pawlotsky
No abstract text is available yet for this article.
October 21, 2019: Journal of Hepatology
Ying-Chun Shen, Chia-Lang Hsu, Yung-Ming Jeng, Ming-Chih Ho, Cheng-Maw Ho, Chin-Ping Yeh, Chia-Yu Yeh, Meng-Chi Hsu, Ray-Heng Hu, Ann-Lii Cheng
BACKGROUND AND AIMS: Tumor heterogeneity has been frequently reported in patients with hepatocellular carcinoma (HCC). The reliability of single-region tumor samples for evaluating immune tumor microenvironment is also debatable. We conducted a prospective study to analyze the similarity in immune tumor microenvironments among different regions of a single tumor. METHODS: Multiregion sampling was performed from newly resected tumors. The immune tumor microenvironment was evaluated by immunohistochemical (IHC) staining of programmed cell death receptor ligand 1 (PD-L1), CD4, CD8, CD20, forkhead box P3, dendritic cell-lysosomal associated membrane protein, CD68, myeloperoxidase, and tertiary lymphoid structures (TLSs)...
October 18, 2019: Journal of Hepatology
Mohammad Shadab Siddiqui, Mark L Van Natta, Margery A Connelly, Raj Vuppalanchi, Brent A Neuschwander-Tetri, James Tonascia, Cynthia Guy, Rohit Loomba, Srinivasan Dasarathy, Julia Wattacheril, Naga Chalasani, Arun J Sanyal
BACKGROUND: Farnesoid X receptor (FXR) agonist, obeticholic acid (OCA), increases total and low-density lipoprotein cholesterol (LDL-C) in patients with nonalcoholic steatohepatitis (NASH). The present study evaluated the impact of OCA therapy on lipoprotein sub-particles. METHOD: The study included 196 patients (99 OCA group and 97 placebo) who were enrolled in the FLINT trial and had samples available for lipid analysis and liver biopsies at enrollment and end-of-treatment (EOT) at 72 weeks...
October 18, 2019: Journal of Hepatology
Mònica Pons, Sergio Rodríguez-Tajes, Juan Ignacio Esteban, Zoe Mariño, Víctor Vargas, Sabela Lens, Maria Buti, Salvador Augustin, Xavier Forns, Beatriz Mínguez, Joan Genescà
BACKGROUND &AIMS: We aimed to describe the incidence of liver related events (LRE) in a population of hepatitis C compensated advanced chronic liver disease (cACLD) patients who achieved sustained virological response (SVR) after direct-acting antiviral (DAA) therapy and identify non-invasive parameters to predict the occurrence of LRE. METHODS: This two-center prospective study included 572 cACLD patients who had been treated with DAA and had achieved SVR. Patients had liver stiffness measurement (LSM) ≥10 kPa at baseline and had never decompensated (Child Pugh class A)...
October 17, 2019: Journal of Hepatology
Michael Linecker, Florin Botea, Dimitri Aristotele Raptis, Diana Nicolaescu, Përparim Limani, Ruslan Alikhanov, Pavel Kim, Andrea Wirsching, Philipp Kron, Marcel A Schneider, Christoph Tschuor, Patryk Kambakamba, Christian Oberkofler, Michelle L De Oliveira, John Bonvini, Michail Efanov, Rolf Graf, Henrik Petrowsky, Igor Khatkov, Pierre-Alain Clavien, Irinel Popescu
OBJECTIVE: To investigate the perioperative use of Omega-3 polyunsaturated fatty acids (Ω3-FA) to reduce post-operative complications after liver surgery. SUMMARY BACKGROUND DATA: In a variety of animal models, Ω3-FA disclosed strong protective effects in alleviating hepatic ischemia/reperfusion injury and steatosis with enhancement of regeneration after major tissue loss. Given these benefits along with its safety profile, we hypothesized that perioperative administration of Ω3-FA in patients undergoing liver surgery may ameliorate the post-operative course...
October 15, 2019: Journal of Hepatology
Valerio Giannelli, Olivier Roux, Cédric Laouénan, Pauline Manchon, Floriane Ausloos, Delphine Bachelet, Pierre-Emmanuel Rautou, Emmanuel Weiss, Richard Moreau, Alexandre Mebazaa, Alain Cohen-Solal, François Durand, Claire Francoz
BACKGROUND & AIMS: Whether non-selective beta blockers (NSBBs) are deleterious in patients with end stage cirrhosis and refractory ascites or not is debated with contrasting results. We hypothesized that only a subset of patients with impaired cardiac performance could be at increased risk of mortality on the waiting list for liver transplantation if receiving NSBBs. METHODS: The study included 584 consecutive patients with cirrhosis evaluated for transplantation between 1999 and 2014...
October 14, 2019: Journal of Hepatology
Agustín Albillos, Andrea de Gottardi, María Rescigno
The gut-liver axis refers to the bidirectional relationship between the gut and its microbiota, and the liver, resulting from the integration of signals generated by dietary, genetic and environmental factors. This reciprocal interaction is established through the vascular route of the portal vein that carries gut-derived products directly to the liver, and the liver feed-back route of bile and antibody secretion to the intestine. The intestinal mucosal and vascular barrier is the functional and anatomical structure that serves as a playground for the interactions between the gut and the liver, limiting the systemic dissemination of microbes and toxins while allowing nutrients to access the circulation and to reach the liver...
October 14, 2019: Journal of Hepatology
Juan Macías
No abstract text is available yet for this article.
October 11, 2019: Journal of Hepatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"